Peter Attia· MD
so billions of patient year data on metformin I know that from an FDA standpoint the highest priority is safety that's a low bar to cross the more interesting one from the standpoint of this study is actual efficacy right
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so billions of patient year data on metformin I know that from an FDA standpoint the highest priority is safety that's a low bar to cross the more interesting one from the standpoint of this study is actual efficacy right
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
you know the best data on that it's not good for muscle function but again that comes from early work and i think we have a a long ways to go because it's so safe you know that's the that's the big thing about metformin is that we know it's extremely safe it's been taken by millions of people we don't know that about rapamycin yet but i think it ought to be a high priority to find out what low-dose rapamycin does